癌相关成纤维细胞在非小细胞肺癌进展中的作用

doi:10.11904/j.issn.1002-3070.2023.04.014

Abstract

Abstract: Cancer-associated fibroblasts(CAFs)are the main components of the matrix and associated tumor microenvironment, playing an important role in the occurrence and development of non-small cell lung cancer(NSCLC). Many studies have demonstrated that CAFs are involved in regulating the proliferation, invasion, metastasis, and resistance to chemotherapy drugs of cancer cells by secreting various types of cytokines and chemokines, growth factors, and extracellular matrix proteins. This article will review the source, activation mechanisms, and role of CAFs in the occurrence and development of NSCLC, so as to gain a deeply understanding the progression mechanism of NSCLC and provide new ideas for its treatment.

Key words: Cancer-associated fibroblasts, Tumor microenvironment, Non-small cell lung cancer

CLC Number:

R734.2

CAO Yingyue, PANG Luyi, ZHANG Jian, JIN Shi. The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer[J]. Journal of Practical Oncology, 2023, 37(4): 383-388.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.04.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I4/383

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Hirsch FR,Scagliotti GV,Mulshine JL,et al.Lung cancer:current therapies and new targeted treatments[J].Lancet,2017,389(10066):299-311.
3 Erez N,Truitt M,Olson P,et al.Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner[J].Cancer Cell,2010,17(2):135-147.
4 Wu F,Yang J,Liu J,et al.Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer[J].Signal Transduct Target Ther,2021,6(1):218.
5 Shintani Y,Fujiwara A,Kimura T,et al.IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling[J].J Thorac Oncol,2016,11(9):1482-1492.
6 Shintani Y,Kimura T,Funaki S,et al.Therapeutic targeting of cancer-associated fibroblasts in the non-small cell lung cancer tumor microenvironment[J].Cancers(Basel),2023,15(2).335.
7 Orimo A,Weinberg RA.Heterogeneity of stromal fibroblasts in tumors[J].Cancer Biol Ther,2007,6(4):618-619.
8 Sugimoto H,Mundel TM,Kieran MW,et al.Identification of fibroblast heterogeneity in the tumor microenvironment[J].Cancer Biol Ther,2006,5(12):1640-1646.
9 Pietras K,Sjoblom T,Rubin K,et al.PDGF receptors as cancer drug targets[J].Cancer Cell,2003,3(5):439-443.
10 Kalluri R.The biology and function of fibroblasts in cancer[J].Nat Rev Cancer,2016,16(9):582-598.
11 Aoyagi Y,Yokose T,Minami Y,et al.Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma[J].Cancer Res,2001,61(21):7950-7954.
12 Petersen OW,Nielsen HL,Gudjonsson T,et al.Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma[J].Am J Pathol,2003,162(2):391-402.
13 Borriello L,Nakata R,Sheard MA,et al.Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells[J].Cancer Res,2017,77(18):5142-5157.
14 Chen H,Zhao L,Meng Y,et al.Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression[J].Cancer Lett,2022,536:215611.
15 Shi L,Zhu W,Huang Y,et al.Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer[J].Clin Transl Med,2022,12(7):e989.
16 Gentles AJ,Hui AB,Feng W,et al.A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk[J].Genome Biol,2020,21(1):107.
17 Tyan SW,Kuo WH,Huang CK,et al.Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis[J].PLoS One,2011,6(1):e15313.
18 Shien K,Papadimitrakopoulou VA,Ruder D,et al.JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer[J].Mol Cancer Ther,2017,16(10):2234-2245.
19 Zhuang H,Jiang H,Zhu L,et al.Cancer-associated fibroblasts in non-small cell lung cancer:recent advances and future perspectives[J].Cancer Lett,2021,5(14):38-47.
20 Kim SH,Choe C,Shin YS,et al.Human lung cancer-associated fibroblasts enhance motility of non-small cell lung cancer cells in co-culture[J].Anticancer Res,2013,33(5):2001-2009.
21 Saito RA,Micke P,Paulsson J,et al.Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer[J].Cancer Res,2010,70(7):2644-2654.
22 Xu LN,Xu BN,Cai J,et al.Tumor-associated fibroblast-conditioned medium promotes tumor cell proliferation and angiogenesis[J].Genet Mol Res,2013,12(4):5863-5871.
23 Fromigue O,Louis K,Dayem M,et al.Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation,angiogenesis,cell growth and survival[J].Oncogene,2003,22(52):8487-8497.
24 Chi JY,Hsiao YW,Liu HL,et al.Fibroblast CEBPD/SDF4 axis in response to chemotherapy-induced angiogenesis through CXCR4[J].Cell Death Discov,2021,7(1):94.
25 Tran E,Chinnasamy D,Yu Z,et al.Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia[J].J Exp Med,2013,210(6):1125-1135.
26 Galindo M,Santiago B,Rivero M,et al.Chemokine expression by systemic sclerosis fibroblasts:abnormal regulation of monocyte chemoattractant protein 1 expression[J].Arthritis Rheum,2001,44(6):1382-1386.
27 Kinoshita T,Ishii G,Hiraoka N,et al.Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma[J].Cancer Sci,2013,104(4):409-415.
28 Inoue C,Miki Y,Saito R,et al.PD-L1 Induction by cancer-qssociated fibroblast-derived factors in lung qdenocarcinoma cells[J].Cancers(Basel),2019,11(9):1257.
29 Teramoto K,Igarashi T,Kataoka Y,et al.Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer[J].Lung Cancer,2019,137:56-63.
30 Lakins MA,Ghorani E,Munir H,et al.Cancer-associated fibroblasts induce antigen-specific deletion of CD8(+)T Cells to protect tumour cells[J].Nat Commun,2018,9(1):948.
31 Liu T,Zhou L,Li D,et al.Cancer-associated fibroblasts build and secure the tumor microenvironment[J].Front Cell Dev Biol,2019,7:60.
32 Calco F,Ege N,Grande-Garcia A,et al.Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts[J].Nat Cell Biol,2013,15(6):637-646.
33 Santos AM,Jung J,Aziz N,et al.Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice[J].J Clin Invest,2009,119(12):3613-3625.
34 De P,Aske J,Sulaiman R,et al.Bete noire of chemotherapy and targeted therapy:CAF-mediated resistance[J].Cancers(Basel),2022,14(6):1519.
35 Scott AM,Wiseman G,Welt S,et al.A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer[J].Clin Cancer Res,2003,9(5):1639-1647.
36 Eager RM,Cunningham CC,Senzer N,et al.Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer[J].Clin Oncol(R Coll Radiol),2009,21(6):464-472.
37 Sum E,Rapp M,Durr H,et al.The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation[J].J Immunother Cancer,2022,10(3):e003264.
38 Sum E,Rapp M,Frobel P,et al.Fibroblast activation protein alpha-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity[J].Clin Cancer Res,2021,27(14):4036-4053.
39 Duperret EK,Trautz A,Ammons D,et al.Alteration of the tumor stroma using a consensus DNA vaccine targeting fibroblast activation protein(FAP)synergizes with antitumor vaccine therapy in mice[J].Clin Cancer Res,2018,24(5):1190-1201.
40 Xie J,Yuan S,Peng L,et al.Antitumor immunity targeting fibroblast activation protein-alpha in a mouse lewis lung carcinoma model[J].Oncol Lett,2020,20(1):868-876.
41 Kakarla S,Chow KK,Mata M,et al.Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma[J].Mol Ther,2013,21(8):1611-1620.
42 Bayliss TJ,Smith JT,Schuster M,et al.A humanized anti-IL-6 antibody(ALD518)in non-small cell lung cancer[J].Expert Opin Biol Ther,2011,11(12):1663-1668.
43 Dijkgraaf EM,Santegoets SJ,Reyners AK,et al.A phase I trial combining carboplatin/doxorubicin with tocilizumab,an anti-IL-6R monoclonal antibody,and interferon-alpha2b in patients with recurrent epithelial ovarian cancer[J].Ann Oncol,2015,26(10):2141-2149.
44 Hegab AE,Ozaki M,Kameyama N,et al.Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts[J].J Pathol,2019,249(2):193-205.
45 Xiang H,Ramil CP,Hai J,et al.Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma[J].Cancer Immunol Res,2020,8(4):436-450.

[1]	MIAO Ling, ZHAO Zhihan, WANG Min. Levels and clinical significance of PA28γ and miR-7-5p in tumor tissues of patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 344-350.
[2]	CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation [J]. Journal of Practical Oncology, 2023, 37(3): 262-266.
[3]	LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying. The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation [J]. Journal of Practical Oncology, 2023, 37(2): 117-122.
[4]	LIU Xinxin, MA Xiyuan, MIU Meiqi, WANG Yuqing, CHEN Jing. Research progress on the role of IL-6 and its receptor in the treatment of breast cancer [J]. Journal of Practical Oncology, 2023, 37(2): 149-154.
[5]	XU Zihan, YU Guohua, NIE Yuhui, SUN Mengmeng, FENG Hui, LIU Shuzhen. Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome [J]. Journal of Practical Oncology, 2022, 36(6): 544-550.
[6]	ZHANG Shumin, ZHANG Gong. Research progress of ILC2s in tumor immune regulation [J]. Journal of Practical Oncology, 2022, 36(6): 566-569.
[7]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.
[8]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[9]	LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(5): 463-467.
[10]	SUN Fusheng, XU Ye, ZHANG Yongjian, LOU Ge. Research progress and new treatment strategies of ovarian cancer organoids [J]. Journal of Practical Oncology, 2022, 36(4): 346-350.
[11]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[12]	ZHANG Hao, YANG Xinguan, HE Yong. Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC [J]. Journal of Practical Oncology, 2022, 36(3): 214-219.
[13]	LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment [J]. Journal of Practical Oncology, 2022, 36(3): 250-254.
[14]	LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(2): 167-172.
[15]	ZHANG Mengru, CAO Dedong, GE Wei. Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(1): 20-25.

The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments